US Stock Market News | LaiLi Financial Raises Target Price to $26, Novavax Pharmaceuticals Rises Over 3%

智通财经
2024.10.10 15:01

周四，诺瓦瓦克斯医药震荡走高一度上涨逾 5%，截至发稿，涨逾 3%，报 13.08 美元。消息面上，莱利金融分析师 Mayank Mamtani 维持诺瓦瓦克斯医药 “买入” 评级，并将目标价从 23 美元上调至 26 美元。

智通财经 APP 获悉，周四，诺瓦瓦克斯医药 (NVAX.US) 震荡走高一度上涨逾 5%，截至发稿，涨逾 3%，报 13.08 美元。消息面上，莱利金融分析师 Mayank Mamtani 维持诺瓦瓦克斯医药 “买入” 评级，并将目标价从 23 美元上调至 26 美元。

Source: 智通财经 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.